Amgen makes regenerative medicine play, backing $25M Fortuna round to move neural stem cells into the clinic

Amgen’s VC wing has invested in Fortuna Fix to help move autologous neural stem cells into the clinic. The $25 million series B sets regenerative medicine startup Fortuna up to move candidates against Parkinson’s disease and spinal cord injury to clinical trials next year.

• Source: Fiercebiotech
• 571
• November 14, 2017